micro-community-banner
Profile Image
  • Add Media
  • Saved

Yesterday
DDW 2026 highlights colorectal cancer screening, GLP-1 research, and Crohn’s disease therapy

Asma Shaukat, MD, Professor of Medicine at NYU Grossman School of Medicine and outgoing Chair of the Clinical Practice Section for the AGA Council, discussed 13-year Nordic trial findings showing reduced colorectal cancer incidence with colonoscopy screening, along with emerging data on GLP-1 therapies in fatty liver disease and cirrhosis. Bruce Sands, MD, Chief of Gastroenterology and Professor of Medicine at the Icahn School of Medicine at Mount Sinai, presented findings from the DUET-CD study evaluating combination therapy in Crohn’s disease.

Profile Image
  • Saved

2d
Cardinal trial: Tonlamarsen shows sustained RAAS suppression and BP reduction in uncontrolled hypertension at ACC 2026

Dr. Luke Laughlin (Preventive Cardiologist, Cleveland Clinic) presented the Cardinal trial at ACC 2026, where Tonlamarsen, an investigational antisense oligonucleotide, reduced angiotensinogen by 67% with ongoing dosing and maintained 23% suppression after a single dose. Despite biochemical differences, both groups achieved similar ~7 mmHg systolic BP reductions, suggesting BP lags behind RAAS suppression. The upcoming Cardinal-ASH study will target acute severe hypertension patients to further evaluate its impact.

Profile Image
  • Saved

1w
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. - PubMed

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41824552

Explore the 2026 guidelines on dyslipidemia management, highlighting new approaches to managing cholesterol and related disorders effectively.


The 2026 guidelines replace the 2018 guidelines, offering updated recommendations for managing dyslipidemia, focusing on evaluation, management, and monitoring of lipid disorders.

Profile Image
  • Saved

1w
A review of the association between abnormal body mass index and oocyte quality - PubMed

A review of the association between abnormal body mass index and oocyte quality - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42226234/

In recent years, the global prevalence of obesity has witnessed a sharp increase. Abnormal body mass index (BMI) exerts a profound influence on female fertility, particularly on oocyte quality. This...

Review highlights that abnormal BMI—especially obesity—negatively affects oocyte quality through lipotoxicity, mitochondrial dysfunction, oxidative stress, DNA damage, and epigenetic alterations, leading to poorer fertility outcomes and increased miscarriage risk.

Profile Image
  • Saved

2w
Combined Probiotic Lactiplantibacillus plantarum ECGC 13110402 and Plant Sterol Supplement May Improve Lipids and Gut Microbiota in Coeliac Adults: A Randomised, Placebo-Controlled Pilot Human Intervention Study - PubMed

Combined Probiotic Lactiplantibacillus plantarum ECGC 13110402 and Plant Sterol Supplement May Improve Lipids and Gut Microbiota in Coeliac Adults: A Randomised, Placebo-Controlled Pilot Human Intervention Study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42197276/

Evidence suggests that a gluten-free diet may increase the risk of metabolic abnormalities associated with cardiovascular disease in adults with Coeliac Disease (CeD). This 9-week, double-blind, placebo-controlled, randomised pilot study...

Pilot randomized placebo-controlled study suggests a combined Lactiplantibacillus plantarum ECGC 13110402 and plant sterol/stanol supplement may improve lipid profiles, increase vitamin D levels, and favorably modulate gut microbiota in adults with coeliac disease and hypercholesterolemia.

Profile Image